{"id":"W4379335592","doi":"10.1200/jco.2023.41.16_suppl.5053","title":"Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pfizer","keywords":"Medicine; Anemia; Enzalutamide; Population; Adverse effect; Placebo; Internal medicine; Prostate cancer; Phases of clinical research; Cancer; Clinical trial; Oncology; Androgen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001191713,0.0005501605,0.0008024329,0.0003508407,0.0001774501,0.0004597943,0.0003429637,0.0004225542,0.002640236],"category_scores_gemma":[0.0008196172,0.0002340729,0.0007639453,0.0003397357,0.0003256854,0.000338992,0.000177044,0.0009608081,0.0002898819],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000375858,"about_ca_system_score_gemma":0.0005274372,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004840952,"about_ca_topic_score_gemma":0.002149922,"domain_scores_codex":[0.9996923,0.0001778714,0.00002326592,0.00003616028,0.00004149309,0.00002890947],"domain_scores_gemma":[0.9995927,0.0001062561,0.0001651342,0.0000218655,0.00002272991,0.00009126191],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.766434,0.01187921,0.01276814,0.00257959,0.004034999,0.0002305255,0.0001453335,0.002147325,0.03193343,0.0002224184,0.002873575,0.1647515],"study_design_scores_gemma":[0.5955175,0.3350727,0.05039484,0.0001392679,0.003870031,0.0007883715,0.00006027526,0.001856819,0.007006979,0.000263978,0.004983838,0.00004536683],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882718,0.008050998,0.0004316885,0.0002146951,0.00005030911,0.0006984632,0.0009615977,0.00007322377,0.001247303],"genre_scores_gemma":[0.993859,0.003082198,0.000584559,0.0003171546,0.00009369139,0.0003276263,0.001017545,0.00001065079,0.0007076322],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002640236,"threshold_uncertainty_score":0.008832514,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2555456283340872,"score_gpt":0.5647169066209956,"score_spread":0.3091712782869084,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}